OABI
OmniAb, Inc.About OABI
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Company
- Headquarters
- Emeryville, CA
- Employees
- 89 (2026)
- Listed
- Nov 1, 2022
- Exchange
- Nasdaq
- Website
- omniab.com
- SEC industry
- Services-Commercial Physical & Biological Research
- Cylvex sector
- Health Care · Life Sciences Tools
Life Sciences Tools
- Market cap #21 of 37
- P/B #18 of 34
Ranked highest first among stocks Cylvex covers.
- TMOThermo Fisher Scientific Inc$256.4B-2.21%
- DHRDanaher Corporation$162.8B-2.30%
- AAgilent Technologies Inc.$49.32B-3.43%
- WATWaters Corp$45.23B-4.10%
- IQVIQVIA Holdings Inc.$43.67B-3.54%
Financial summary
Related companies
About
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.